A Retrospective Review of Tocilizumab for the Management of Blinatumomab (a Bispecific T Cell Engager)-Induced Cytokine Release Syndrome (CRS)

被引：10
|
作者：
Choudhry, Jessica [1 ]
Parson, Mandy [1 ]
Wright, Jacqueline [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-117353
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5211
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.
    van de Donk, Niels W. C. J.
    Garfall, Alfred L.
    Benboubker, Lotfi
    Uttervall, Katarina
    Groen, Kaz
    Rosinol, Laura
    Hodin, Caroline
    Stephenson, Tara
    Trancucci, Danielle
    Perales-Puchalt, Alfredo
    Kobos, Rachel
    Banerjee, Arnob
    Mateos, Maria-Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Rationale for combining tyrosine kinase inhibitors and T cell redirecting antibodies to mitigate cytokine release syndrome (CRS)
    Leclercq-cohen, Gabrielle
    Bacac, Marina
    Klein, Christian
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (03) : 223 - 225
  • [33] DASATINIB AS A RAPID PHARMACOLOGICAL ON/OFF SWITCH FOR T CELL BISPECIFIC ANTIBODY-INDUCED T CELL ACTIVATION AND CYTOKINE RELEASE
    Leclercq, Gabrielle
    Haegel, Helene
    Schneider, Anneliese
    Berger, Estelle Marrer
    Walz, Antje
    Boetsch, Christophe
    Pulko, Vesna
    Ferlini, Cristiano
    Klein, Christian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A391 - A392
  • [34] Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
    Goebeler, Maria-Elisabeth
    Bargou, Ralf
    LEUKEMIA & LYMPHOMA, 2016, 57 (05) : 1021 - 1032
  • [35] Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
    Zhu, Min
    Wu, Benjamin
    Brandl, Christian
    Johnson, Jessica
    Wolf, Andreas
    Chow, Andrew
    Doshi, Sameer
    CLINICAL PHARMACOKINETICS, 2016, 55 (10) : 1271 - 1288
  • [36] Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
    Min Zhu
    Benjamin Wu
    Christian Brandl
    Jessica Johnson
    Andreas Wolf
    Andrew Chow
    Sameer Doshi
    Clinical Pharmacokinetics, 2016, 55 : 1271 - 1288
  • [37] Management of cytokine release syndrome related to CAR-T cell therapy
    Chen, Hongli
    Wang, Fangxia
    Zhang, Pengyu
    Zhang, Yilin
    Chen, Yinxia
    Fan, Xiaohu
    Cao, Xingmei
    Liu, Jie
    Yang, Yun
    Wang, Baiyan
    Lei, Bo
    Gu, Liufang
    Bai, Ju
    Wei, Lili
    Zhang, Ruili
    Zhuang, Qiuchuan
    Zhang, Wanggang
    Zhao, Wanhong
    He, Aili
    FRONTIERS OF MEDICINE, 2019, 13 (05) : 610 - 617
  • [38] Management of cytokine release syndrome related to CAR-T cell therapy
    Hongli Chen
    Fangxia Wang
    Pengyu Zhang
    Yilin Zhang
    Yinxia Chen
    Xiaohu Fan
    Xingmei Cao
    Jie Liu
    Yun Yang
    Baiyan Wang
    Bo Lei
    Liufang Gu
    Ju Bai
    Lili Wei
    Ruili Zhang
    Qiuchuan Zhuang
    Wanggang Zhang
    Wanhong Zhao
    Aili He
    Frontiers of Medicine, 2019, 13 : 610 - 617
  • [39] ALLEVIATION OF OKT3-INDUCED CYTOKINE RELEASE SYNDROME (CRS) WITH PENTOXIFYLLINE (PTX)
    HOLDAAS, H
    WAAGE, A
    BENTDAL, O
    SUNDAL, E
    HARTMANN, A
    NORDAL, K
    FAUCHALD, P
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 1011 - 1011
  • [40] Tetracyclines Enhance Anti-tumor T-Cell Responses Induced by a Bispecific T-Cell Engager
    Noguchi, Yuki
    Yamamoto, Yoko
    Iwahori, Kota
    Matsumoto, Mitsunobu
    Hirata, Michinari
    Okuyama, Hiroomi
    Shintani, Yasushi
    Kumanogoh, Atsushi
    Wada, Hisashi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2022, 45 (04) : 429 - 437
12345